Moderna Inc. announced its Q2 results on Thursday before the bell.
Key Highlights:
- Moderna Reports Second Quarter Fiscal Year 2021 Financial Results and Provides Business Updates.
- Moderna COVID-19 Vaccine mRNA-1273: Final blinded analysis of Phase 3 COVE study shows 93% efficacy; Efficacy remains durable through six months after second dose
- Moderna booster candidates demonstrate robust antibody responses to COVID-19 variants of concern in Phase 2
- Dosing started in Phase 1 studies for quadrivalent seasonal flu vaccine candidate (mRNA-1010) and IL-2 mRNA program for autoimmune disorders (mRNA-6231)
- Moderna has mRNA candidates in clinical development across five therapeutic areas: infectious disease, cardiovascular, oncology, rare disease and autoimmune disorders
- Q2 total revenue of $4.4 billion, net income of $2.8 billion and diluted earnings per share of $6.46
- Moderna establishes new Charitable Foundation to promote public health, healthcare and educational opportunities, particularly in underserved populations
https://risingcandle.com/business/moderna-announces-q2-results-crushes-earnings/
Submitted August 05, 2021 at 09:04AM by lazywizard99 https://ift.tt/3fATjSB
